WallStSmart

Baird Medical Investment Holdings Limited (BDMD)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 288363% more annual revenue ($65.01B vs $22.54M). MRK leads profitability with a 28.1% profit margin vs -121.0%. MRK earns a higher WallStSmart Score of 59/100 (C).

BDMD

Avoid

21

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 6.7Quality: 4.0
Piotroski: 1/9Altman Z: 0.72

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDMDUndervalued (+68.1%)

Margin of Safety

+68.1%

Fair Value

$2.63

Current Price

$1.72

$0.91 discount

UndervaluedFair: $2.63Overvalued
MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$110.95

$14.47 premium

UndervaluedFair: $96.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDMD1 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

BDMD4 concerns · Avg: 2.5/10
Market CapQuality
$67.58M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-77.6%2/10

ROE of -77.6% — below average capital efficiency

Revenue GrowthGrowth
-39.0%2/10

Revenue declined 39.0%

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : BDMD

The strongest argument for BDMD centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bear Case : BDMD

The primary concerns for BDMD are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BDMD profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.28 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 21/100), backed by strong 28.1% margins. BDMD offers better value entry with a 68.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baird Medical Investment Holdings Limited

HEALTHCARE · MEDICAL DEVICES · USA

Baird Medical Investment Holdings Limited, along with its subsidiaries manufactures microwave ablation and other medical devices for minimally invasive tumor treatment. The company is headquartered in Guangzhou, China.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?